戴维医疗(300314) - 2022 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2022 was ¥97,715,502.09, representing a 2.82% increase compared to ¥95,038,385.91 in the same period last year[3] - Net profit attributable to shareholders decreased by 56.43% to ¥9,586,811.39 from ¥22,002,474.79 year-on-year[3] - The net profit for the first quarter of 2022 was CNY 9,586,811.39, a decrease of 56.4% compared to CNY 22,002,474.79 in the same period last year[20] - Operating profit for the first quarter was CNY 13,736,362.05, down 40.5% from CNY 23,140,942.38 year-over-year[20] - The total profit for the first quarter was CNY 13,530,042.77, a decrease of 43.3% from CNY 23,994,912.21 year-over-year[20] Cash Flow and Investments - The net cash flow from operating activities improved by 66.33%, reaching -¥17,914,205.73 compared to -¥53,198,078.06 in the previous year[7] - The company reported a cash inflow from investment activities of CNY 353,008,146.03, down from CNY 402,956,907.55 year-over-year[24] - The company incurred an investment loss of CNY 12,519,228.93, compared to a gain of CNY 3,552,828.26 in the previous year[20] - The company did not distribute dividends during the reporting period, resulting in a 100% increase in cash flow from financing activities, which was ¥0.00 compared to -¥43,214,611.71 in the previous year[7] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,142,384,274.03, a decrease of 1.17% from ¥1,155,886,846.70 at the end of the previous year[3] - The total liabilities decreased to CNY 142,270,779.49 from CNY 165,360,163.55, representing a reduction of approximately 13.9%[16] - The total assets as of March 31, 2022, were CNY 1,142,384,274.03, a decrease from CNY 1,155,886,846.70 at the end of the previous quarter, showing a decline of about 1.2%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,508, with the top three shareholders holding a combined 66.06% of the shares[9] - Basic and diluted earnings per share were both CNY 0.03, down from CNY 0.08 in the same quarter last year[21] Operating Costs and Expenses - The total operating costs for Q1 2022 amounted to CNY 77,461,419.14, up from CNY 75,524,238.26 in the previous year, indicating an increase of about 2.6%[18] - Research and development expenses for Q1 2022 were CNY 7,723,486.29, down from CNY 8,869,999.84 in the previous year, indicating a decrease of approximately 12.9%[18] Other Income and Subsidies - The company received government subsidies amounting to ¥5,920,742.36, contributing to a 945.66% increase in other income[6] - The accounts receivable increased by 78.50% to ¥28,192,090.16, primarily due to increased credit terms extended to distributors[6] - The accounts receivable increased to CNY 28,192,090.16 from CNY 15,794,123.05, representing a significant increase of about 78.5%[15]